Document Type : Original Research Article


1 Department of Medicinal Chemistry, School of Pharmacy and Pharmaceutical Sciences Branch, Isfahan University of Medical Sciences, Isfahan, Iran

2 Biosensor Research Center, School of Advanced Technologies in Medicine, Isfahan University of Medical Sciences, Isfahan, Iran



Antidepressant activity of curcumin (Cur), as a very well–known herbal product, has been investigated within this work. Two tautomeric forms of Cur–a and Cur–b in addition to the reference structure of Moclobemide (Moc) have been optimized first to evaluate molecular descriptors for ligands. Subsequently, monoamine oxidase–A (MAO–A) has been prepared as receptor for molecular docking (MD) simulation. Interacting systems of ligand–receptor have been very well determined in both of quantitative and qualitative aspects. The results indicated that both of Cur–a and Cur–b are good ligands for interactions with MAO–A even better than Moc, in which Cur–a is more favorable, But based on the interaction of Moc with flavin group of MAO–A, Cur could be employed as a complementary compound for antidepressant activity. All the interacting mechanism of ligand–receptor are very well recognized with this work. 

Graphical Abstract

Antidepressant Activity of Curcumin by Monoamine Oxidase–A Inhibition


  1. Depression and other common mental disorders: global health estimates. World Health Organization, 2017.
  2. Diagnostic and statistical manual of mental disorders (DSM–5®): American Psychiatric Association, 2013.
  3. G.J. Peng, J.S. Tian, X.X. Gao, Y.Z. Zhou, X.M. Qin; Research on the pathological mechanism and drug treatment mechanism of depression. Cur. Neuropharmacol. 13 (2015) 514–23.
  4. S.K. Al–Nuaimi, E.M. MacKenzie, G.B. Baker; Monoamine oxidase inhibitors and neuroprotection: a review. Am. J. Therapeuts. 19 (2012) 436–48.
  5. S. Caroline, M.G.C. Zeind; Depressive Disorders. In Applied Therapeutics, the Clinical Use of Drugs 2017, p 1813–1833.
  6. M. Bortolato, K. Chen, J.C. Shih; Monoamine oxidase inactivation: from pathophysiology to therapeutics. Adv. Drug Delivery Rev. 60 (2008) 1527–1533.
  7. K.I. Shulman, N. Herrmann, S.E. Walker SE; Current place of monoamine oxidase inhibitors in the treatment of depression. CNS Drugs 27 (2013) 789–797.
  8. T. Szafrański; Herbal remedies in depression–state of the art. Psychiatr. Pol. 48 (2014) 59–73.
  9. D. Vina, S. Serra, M. Lamela, G. Delogu; Herbal natural products as a source of monoamine oxidase inhibitors: A review. Cur. Topics Med. Chem. 20 (2012) 2131–2144.
  10. S. Prasad, S.C. Gupta, A.K. Tyagi, B.B. Aggarwal; Curcumin, a component of golden spice: from bedside to bench and back. Biotechnol. Adv.32 (2014) 1053–1064.
  11. A.B. Kunnumakkara, D. Bordoloi, G. Padmavathi, J. Monisha, N.K. Roy, S. Prasad, et al.; Curcumin, the golden nutraceutical: multitargeting for multiple chronic diseases. British J. Pharmacol. 174 (2017) 1325–1348.
  12. Y. Xu, B.S. Ku, H.Y. Yao, Y.H. Lin, X. Ma, Y.H. Zhang, et al.; The effects of curcumin on depressive–like behaviors in mice. Eur. J. Pharmacol. 518 (2005) 40–46.
  13. S.K. Kulkarni, M.K. Bhutani, M. Bishnoi; Antidepressant activity of curcumin: involvement of serotonin and dopamine system. Psychopharmacol. 201 (2008) 435–442.
  14. Q.X. Ng, S.S.H. Koh, H.W. Chan, C.Y.X. Ho; Clinical use of curcumin in depression: A meta–analysis. J. Am. Med. Direct. Assoc. 18 (2017) 503–508.
  15. T. Partovi, M. Mirzaei, N.L. Hadipour; The C–H···O hydrogen bonding effects on the 17O electric field gradient and chemical shielding tensors in crystalline 1–methyluracil: A DFT study. Z. Naturforsch. A 61 (2006) 383–388.
  16. M. Mirzaei, M. Meskinfam; Computational NMR studies of silicon nanotubes. Comput. Theor. Chem. 978 (2011) 123–125.
  17. M. Mirzaei; Uracil–functionalized ultra–small (n, 0) boron nitride nanotubes (n= 3–6): Computational studies. Superlat. Microstruct. 57 (2013) 44–50.
  18. M. Mirzaei; Effects of carbon nanotubes on properties of the fluorouracil anticancer drug: DFT studies of a CNT–fluorouracil compound. Int. J. Nano Dimens. 3 (2013) 175–179.
  19. M. Mirzaei, R.S. Ahangari; Formations of CNT modified 5–(halogen) uracil hybrids: DFT studies. Superlat. Microstruct. 65 (2014) 375–379
  20. E. Naderi, M. Mirzaei, L. Saghaie, G. Khodarahmi, O. Gulseren; Relaxations of methylpyridinone tautomers at the C60 surfaces: DFT studies. Int. J. Nano Dimens. 8 (2017) 124–131.
  21. H.E. Pence, A. Williams; ChemSpider: an online chemical information resource, 2010.
  22. M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, et al.; Gaussian 09, Revision A.02, Gaussian, Inc., Wallingford CT, 2016.
  23. P.W. Rose, A. Prlić, A. Altunkaya, C. Bi, A.R. Bradley, C.H. Christie, et al.; The RCSB protein data bank: integrative view of protein, gene and 3D structural information. Nucleic Acids Res. 45 (2017) D271–D281.
  24. Dassault Systèmes BIOVIA, Discovery Studio, San Diego: Dassault Systèmes, 2016.
  25. G.M. Morris, R. Huey, W. Lindstrom, M.F. Sanner, R.K. Belew, D.S. Goodsell, A.J. Olson; Autodock4 and AutoDockTools4: automated docking with selective receptor flexiblity. J. Computat. Chem. 16 (2009) 2785–2791.
  26. M. Soleimani, M. Mirzaei, M.R. Mofid, G. Khodarahmi, S.F. Rahimpour; Lactoperoxidase inhibition by tautomeric propylthiouracils. Asian J. Grenn Chem. Article in press.
  27. Z.S. Alidoosti, M. Mirzaei; Comparative Examination of Moclobemide, Tranylcypromine, Phenelzine and Isocarboxazid for Monoamine Oxidase-A Inhibition. . Adv. J. Chem. B 1 (2019) pp
  28. A.N. Esfahani, M. Mirzaei; Flavonoid Derivatives for Monoamine Oxidase–A Inhibition. Adv. J. Chem. B 1 (2019)